Floatz logo

BEBT 908

Relapsed or Refractory Multiple Myeloma

BeBetter Med IncSmall moleculePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Relapsed or Refractory Multiple Myeloma cohort.

Asset / SponsorPhaseRating
qls32015
Qilu Pharmaceutical Co., Ltd.
Phase 3BB
sg301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3B
Encorafenib
University of Heidelberg Medical Center
Phase 2B
Mitoxantrone
Second Affiliated Hospital of Soochow University
Phase 1/2CCC
auy922
Novartis Pharmaceuticals
Phase 1/2CCC

View all 27 →

Same molecule, other indications

BEBT 908 is also rated in:

Relapsed or Refractory Diffuse Large B-cell LymphomaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
Relapsed or Refractory Non-Hodgkin's LymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →